Hidehito HORINOUCHI· @HHorinouchi · X·· 1 day agoScore70
Body · original
🔥SAFFRON: Osimertinib + savolitinib vs platinum-pemetrexed in EGFR-mutated NSCLC with MET overexpression/amp post-osimertinib
🆙 @NEJM #ESMO26
☑Phase 3 RCT; N=338; 12-mo PFS 36 vs 10% (HR 0.55, p<0.001); 12-mo OS 70 vs 53% (HR 0.68, p=0.01)
🎙Dr. Shun Lu @nicogirardcurie
#LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders
https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
89 views · 1 like · 1 repost · 0 replies
🆙#ESMO26 Presidential Symposium II: #LCSM 🔥SAFFRON: Osimertinib (Osi) + Savolitinib (Savo) vs Platinum–Pemetrexed (Plat–Pem) in EGFRm MET-Overexpressed (OE) and/or -Amplified (AMP) Advanced NSCLC Post-Osi: Phase (Ph) 3 Primary Results 🎙️Dr. Shun Lu 🔢LBA6 🎯Significantly Improved BICR-PFS (7.6 vs 5.4mo, HR 0.55; n=338) and OS (17.8 vs 12.9mo, HR 0.68, p=0.010) 🎯Grade≥3 TEAEs 64% vs 63%; Discontinuation 14% vs 8% ☑️NCT05261399 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters在 X 查看被引用的帖子
Source: Hidehito HORINOUCHI · x.com